This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.

Note: We can assist only if the medicine is unavailable in your country.”

Ninlaro (ixazomib)

General Description

Ninlaro (ixazomib) is a prescription medicine used to treat patients with multiple myeloma.

Getting Ninlaro (ixazomib) in India

Ninlaro (ixazomib)is approved in the U.S., Europe, and other countries, but it is not yet commercially available in India. However, eligible patients in India may access this important therapy through the Named Patient Program (NPP).

MitoGENE helps patients obtain Ninlaro (ixazomib) legally and safely, in collaboration with their treating doctor. We assist with documentation, import coordination, and delivery—ensuring full compliance with Indian regulatory guidelines.

If you or a loved one needs Ninlaro (ixazomib), MitoGENE is here to guide you through every step of the process.

Disease Indications:Multiple Myeloma

Manufacturer:Takeda Pharma A/S

Usage:Oral

Medicine Approved by:

  • European Medical Agency (EMA)
  • Food and Drug Administration (FDA)
  • Health Canada
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • Therapeutic Goods Administration (TGA)

Available Dosage Form & Package:

  • 3 capsules of 2.3 mg
  • 3 capsules of 3 mg
  • 3 capsules of 4 mg

Shipping:

Room Temperature Shipping.  Ninlarois shipped under controlled room temperature conditions (15°C to 25°C) using standard logistics procedures.

What is Ninlaro (ixazomib) used for?
Ninlaro (ixazomib) is a proteasome inhibitor prescribed in combination with lenalidomide (Revlimid®) and dexamethasone for treating adults with multiple myeloma who have received at least one prior line of therapy. It is available in capsule form in 2.3 mg, 3 mg, and 4 mg strengths.

How does Ninlaro (ixazomib) work?
Ixazomib works by reversibly inhibiting the proteasome—a key enzyme complex involved in protein degradation, cell division, and survival. Disrupting proteasome function leads to cancer cell death (apoptosis). Laboratory studies showed that ixazomib is active against multiple myeloma cells, including those resistant to other treatments like bortezomib, lenalidomide, and dexamethasone. When used with lenalidomide, it also demonstrated synergistic effects.

How is Ninlaro (ixazomib) taken?
The recommended dose is 4 mg taken orally on Days 1, 8, and 15 of a 28-day cycle. Dose adjustments may be necessary for patients with severe kidney or liver impairment. Ninlaro should be taken at least 1 hour before or 2 hours after eating. Do not crush or open capsules.

Possible side effects of Ninlaro (ixazomib)
Common side effects (≥20%):

  • Diarrhea
  • Constipation
  • Low platelet count (thrombocytopenia)
  • Peripheral neuropathy
  • Nausea or vomiting
  • Swelling (peripheral edema)
  • Back pain

Serious side effects include:

  • Severe thrombocytopenia
  • Severe diarrhea

Use in special populations
Ninlaro can cause harm to unborn babies. It is not recommended during pregnancy or breastfeeding. Both men and women of reproductive potential should use effective birth control during treatment and for 90 days after the last dose.

Always consult your doctor before starting or modifying treatment. Complete prescribing details can be found in the official product information.

References

1. Summary of Product Characteristics: Ninlaro (ixazomib) [PDF]
    Takeda Pharmaceuticals America, Inc., FDA, Nov 2015

2. FDA archive. Ixazomib
    FDA archive, cited Aug 2016

3. Human Medicines: Ninlaro (ixazomib)
    EMA, cited April 2017

4. Summary of Product Characteristics: Ninlaro (ixazomib) [PDF]
    Takeda Pharmaceuticals, EMA, Nov 2016

5. Ninlaro (ixazomib) Receives Conditional Approval from the European Commission to Treat Multiple Myeloma, Takeda Press Release, Nov 2016

6. TGA Public Summary: Ninlaro (ixazomib) [PDF]
    Takeda, Nov 2016

7. Product mongraph [Health Canada]: Ninlaro (ixazomib) [PDF]
    Takeda Canada, Aug 2016

Four Simple Steps to AccessNinlaro (ixazomib)

If Ninlaro (ixazomib) is not yet approved or available commercially in your country, MitoGENE can help you access it through a legal pathway. Here’s how:

    Upload Prescription

    Upload Patient Consent Form

    Patient Consent Form
    Download

    Please download and complete this form, including your signature, and attach it to the request form or email it to info@mitogene.org along with the patient details.